CN111329855B - Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer - Google Patents
Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer Download PDFInfo
- Publication number
- CN111329855B CN111329855B CN202010374910.1A CN202010374910A CN111329855B CN 111329855 B CN111329855 B CN 111329855B CN 202010374910 A CN202010374910 A CN 202010374910A CN 111329855 B CN111329855 B CN 111329855B
- Authority
- CN
- China
- Prior art keywords
- alpha
- breast cancer
- germacrane
- triene
- acetal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer. The invention discovers that 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal has obvious inhibition effect on proliferation of human breast cancer MCF-7 cell strain, human glioma U87 cell strain and human rhabdomyosarcoma RD cell strain, and has a prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Description
Technical Field
The invention relates to the field of medicines, in particular to an application of 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal for resisting human breast cancer.
Background
Cancer is one of the major diseases and serious public health problems seriously threatening human survival and social development, and cancer control has become the key point of the health strategy of governments around the world. In recent years, with global economic development, population aging, lifestyle changes and ecological environment changes, the morbidity and mortality of cancer are on the rise as a whole, and the burden of cancer is increasing.
Breast cancer is a common female malignancy and is on an increasing trend year by year. About 167.1 million new breast cancer cases per year worldwide, about 52.2 million deaths per year result from breast cancer, and the breast cancer incidence in developed countries is relatively higher in less developed countries.
Disclosure of Invention
The invention aims to provide the application of 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal in resisting human breast cancer.
The technical scheme for realizing the purpose is as follows:
the medical application of 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal in preparing medicine for resisting human breast cancer, and the chemical structural formula is as follows:
a medicine for resisting human breast cancer is prepared from 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal as active component and pharmaceutically acceptable adjuvants.
Preferably, the adjuvant may be a solid adjuvant or a liquid adjuvant.
Preferably, the dosage form can be tablets, capsules, granules and injections.
Has the advantages that:
the invention discovers that 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal has obvious inhibition effect on proliferation of human breast cancer MCF-7 cell strain, human glioma U87 cell strain and human rhabdomyosarcoma RD cell strain, and has a prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Drawings
FIG. 1 is a chemical structural formula of 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal;
FIG. 2 is an anti-tumor profile of 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal against 4 tumor cells.
Detailed Description
First, test materials
Human breast cancer MCF-7 cell line, human acute myelogenous leukemia MV4-11 cell line, human glioma U87 cell line and human rhabdomyosarcoma RD cell line were purchased from American ATCC company and frozen in liquid nitrogen.
The purity of 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal is not lower than 98%, the structural formula is shown in figure 1, and the pharmaceutical solution is prepared for standby.
RPMI1640 medium, DMEM medium, fetal bovine serum were purchased from Gibco.
Penicillin, streptomycin was purchased from Sigma.
The CCK8 test kit was purchased from Nanjing Binyan Yuntan.
Second, test method
1. Cell culture
Recovering human breast cancer MCF-7 cell line frozen by liquid nitrogen according to conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin and 100 μ g/ml streptomycin, and culturing at 37 deg.C with 5% CO2And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking cells in logarithmic growth phase for experiment.
Recovering human acute myelogenous leukemia MV4-11 cell line frozen in liquid nitrogen according to conventional method, suspension culturing in RPMI1640 culture solution containing 10% fetal calf serum, 100U/ml penicillin and 100 μ g/ml streptomycin, and culturing at 37 deg.C with 5% CO2And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 days, and taking cells in logarithmic growth phase for experiment.
Recovering human glioma U87 cell line frozen by liquid nitrogen according to conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin, and 100 μ g/ml streptomycin, and culturing at 37 deg.C with 5% CO2And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking cells in logarithmic growth phase for experiment.
Recovering human rhabdomyosarcoma RD cell strain frozen by liquid nitrogen according to conventional method, suspension culturing in DMEM culture solution containing 10% fetal calf serum, 100U/ml penicillin, and 100 μ g/ml streptomycin, at 37 deg.C and 5% CO2And culturing in a constant-temperature incubator with saturated humidity, changing liquid for passage every 2-3 d, and taking cells in logarithmic growth phase for experiment.
2. CCK8 method for determining proliferation inhibition effect of drug on MV4-11 cells
Respectively taking each tumor cell in logarithmic growth phase, digesting and resuspending to prepare the tumor cell with the density of 1.5 multiplied by 10 5The cell suspension/mL is inoculated into a 96-well plate according to the inoculation amount of 90 mu L per well, 10 mu L of drug solutions with different concentrations are added, each concentration is provided with 3 multiple wells, cells cultured without drugs are used as a control group, a culture solution without cells is used as a blank group, and the blank group is placed at 37 ℃ and 5% CO2Culturing in a constant temperature incubator with saturated humidity for 48h, adding each wellAdding 10 uL CCK8 reagent, incubating for 4h, measuring OD450 value of each well at 450nm wavelength of ELISA detector, taking average value of 3 wells, calculating proliferation inhibition rate according to the following formula and calculating IC50 value. Three replicates were run.
The proliferation inhibition rate (%) was [ 1- (OD drug-OD blank)/(OD control-OD blank) ] x 100%.
3. Statistical analysis
Software SPSS17.0 is adopted for statistical analysis processing, the measured data is expressed by mean plus or minus standard deviation, the comparison among groups adopts t test, the comparison among groups adopts variance analysis, and the difference P less than 0.05 has statistical significance.
Third, test results
The IC50 values of 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal for inhibiting the proliferation of various tumor cells are shown in table 1, and as can be seen from table 1, 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal all have excellent proliferation inhibiting effects on human breast cancer MCF-7 cell line, human glioma U87 cell line and human rhabdomyosarcoma RD cell line, and the proliferation inhibiting effect on human acute myelogenous leukemia MV4-11 cell line is not obvious.
TABLE 112 IC50 values for alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal on 4 tumor cells
FIG. 2 is the anti-tumor profile of 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal on 4 tumor cells tested. The anti-tumor spectrum shows that the 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal has obvious inhibition effect on the proliferation of human breast cancer MCF-7 cell strain, human glioma U87 cell strain and human rhabdomyosarcoma RD cell strain, and has the prospect of developing drugs for resisting human breast cancer, human glioma or human rhabdomyosarcoma.
Claims (1)
- Use of 12 α -methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 α -acetal for the preparation of a medicament against human breast cancer; wherein the chemical structural formula of the 12 alpha-methoxy-germacrane-1 (10),4,11(13) -triene-12, 6 alpha-acetal is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010374910.1A CN111329855B (en) | 2020-05-07 | 2020-05-07 | Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010374910.1A CN111329855B (en) | 2020-05-07 | 2020-05-07 | Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111329855A CN111329855A (en) | 2020-06-26 |
| CN111329855B true CN111329855B (en) | 2022-06-28 |
Family
ID=71175390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010374910.1A Active CN111329855B (en) | 2020-05-07 | 2020-05-07 | Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111329855B (en) |
-
2020
- 2020-05-07 CN CN202010374910.1A patent/CN111329855B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Bio-Assay Guided Isolation of Germacranes with Anti-Protozoan Activity from Magnolia sororum;Luis A. Sánchez等;《Natural Product Communications》;20071231;第2卷(第11期);第1065-1069页，尤其是第1065页Figure1，第1067页左栏第1段、Table2，右栏最后1段 * |
| Furanosesquiterpenoids of Commiphora myrrha;Nanqun Zhu等;《J.Nat.Prod》;20011231(第64期);第1460-1462页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111329855A (en) | 2020-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111329855B (en) | Application of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal in resisting human breast cancer | |
| CN102614170A (en) | Application of artemisinin B in preparation of antitumor drugs | |
| CN111419837B (en) | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for anti-human rhabdomyosarcoma | |
| CN111419836B (en) | Use of 12 alpha-methoxy-germacrane-triene-12, 6 alpha-acetal for combating human gliomas | |
| CN111499649A (en) | Benzodifuranone compound with anti-tumor activity, preparation method and application thereof | |
| CN101879173B (en) | Application of Corilagin in preparing anti-tumor drugs | |
| CN101862313A (en) | Application of anthracycline compound in preparing anti-breast cancer medicines | |
| CN102836151A (en) | Application of Brevilin A when serving as JAK-STATs signal target inhibitor | |
| CN109364045B (en) | Heat shock protein 90 inhibitor and application thereof in liver cancer treatment | |
| CN112245425A (en) | Application of isoindolinone compounds in preparation of antitumor drugs | |
| CN111803496A (en) | Use of xanthocapone alkali for treating endometrial cancer | |
| CN111529531B (en) | STAT3 phosphorylation inhibitor and application thereof in preparing medicine for treating acute myeloid leukemia | |
| CN111450096B (en) | Application of phosphorylation inhibitor of STAT3 in preparation of medicine for resisting acute myeloid leukemia | |
| CN109498624B (en) | Anticancer medical application of thiazoline derivative | |
| CN109260194A (en) | Praeruptorin A is alleviating the application in anti-tumor drug Nephrotoxicity Caused By Cisplatin | |
| CN113135861B (en) | Ligustrazine derivative and preparation method and application thereof | |
| CN114306291B (en) | Use of compound in preventing and/or treating cancer | |
| CN114469963B (en) | Application of gliquidone and cisplatin combined drug in preparation of antitumor drugs | |
| CN109432095B (en) | Medical application of thiazoline derivative | |
| CN109602775B (en) | Application of chicory alcohol extract in preparation of anti-breast cancer drugs | |
| CN105503808A (en) | Mutation synthesis of naphthol dimer and preparing method and application of naphthol dimer | |
| CN101601856A (en) | The application of D actinomycin D compounds D actinomycin D V in the preparation medicines resistant to liver cancer | |
| CN109172570B (en) | Application of alkaloid in preparation of medicine for preventing and treating cisplatin drug resistance of lung cancer patient | |
| CN115645382A (en) | Application of compound tetrahydromagnol in preparation of medicine for treating gastric cancer | |
| CN115990147A (en) | Application of metochalcone in preparation of tumor metastasis inhibiting drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220607 Address after: 523878 floor 5, floor 4, building 7, Industrialization Center, No. 19, Alishan Road, Songshanhu high tech Industrial Development Zone, Dongguan City, Guangdong Province Applicant after: Dongguan Lanwei medical laboratory Co.,Ltd. Address before: 211199 Jiangning high tech park, No.42, Xingmin North Road, Jiangning District, Nanjing City, Jiangsu Province Applicant before: Nanjing saierjian Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |